Melanoma-associated Leukoderma - Immunology in Black and White?

Overview

Journal Pigment Cell Melanoma Res

Date 2013 Sep 10

PMID 24010963

Citations 18

Authors

Hadas Prag Naveh

Uma N M Rao

Lisa H Butterfield

Affiliations

Soon will be listed here.

Abstract

Melanoma is an 'immunogenic tumor', often highly infiltrated with lymphocytes, which are capable of inducing regression of the primary tumor. The commonly observed phenomenon of regression suggests substantial cross-talk between immune cells and transformed melanocytes. An immune response to melanocyte differentiation antigens common to transformed and normal melanocytes manifests clinically at distant sites as melanoma-associated vitiligo or halo nevi. Despite similar antigenic targets, the pathogenesis and prognosis differ between the different melanoma-associated leukodermas. Understanding immunologic cross-talk between melanocytes and the immune system will aid the development of approaches to combat melanoma.

Citing Articles

The many faces of autoimmune-mediated melanocyte destruction in melanoma.

Ungureanu L, Vasilovici A, Halmagyi S, Trufin I, Apostu A, Senila S Front Immunol. 2024; 15:1417273.

PMID: 39421737 PMC: 11484273. DOI: 10.3389/fimmu.2024.1417273.

Perception of skin cancer risk and sun protective practices in individuals with vitiligo: a prospective international cross-sectional survey.

Gonzalez S, Mora Hurtado A, Syder N, Rodman J, Elbuluk N Arch Dermatol Res. 2024; 316(5):189.

PMID: 38775848 PMC: 11111492. DOI: 10.1007/s00403-024-02942-0.

Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo.

Rashid S, Molotkov I, Klebanov N, Shaughnessy M, Daly M, Artomov M JID Innov. 2023; 3(6):100217.

PMID: 38034848 PMC: 10685305. DOI: 10.1016/j.xjidi.2023.100217.

Macrophage Reprogramming with Anti-miR223-Loaded Artificial Protocells Enhances In Vivo Cancer Therapeutic Potential.

Lopez-Cuevas P, Xu C, Severn C, Oates T, Cross S, Toye A Adv Sci (Weinh). 2022; 9(35):e2202717.

PMID: 36314048 PMC: 9762313. DOI: 10.1002/advs.202202717.

Current Challenges in Deciphering Sutton Nevi-Literature Review and Personal Experience.

Nedelcu R, Dobre A, Brinzea A, Hulea I, Andrei R, Zurac S J Pers Med. 2021; 11(9).

PMID: 34575681 PMC: 8470687. DOI: 10.3390/jpm11090904.

References

Butterfield L, Comin-Anduix B, Vujanovic L, Lee Y, Dissette V, Yang J . Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008; 31(3):294-309. PMC: 3651040. DOI: 10.1097/CJI.0b013e31816a8910. View

Nazarian R, Prieto V, Elder D, Duncan L . Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 2010; 37 Suppl 1:41-7. DOI: 10.1111/j.1600-0560.2010.01505.x. View

Hodgkinson C, Moore K, Nakayama A, Steingrimsson E, Copeland N, Jenkins N . Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell. 1993; 74(2):395-404. DOI: 10.1016/0092-8674(93)90429-t. View

Bandarchi B, Jabbari C, Vedadi A, Navab R . Molecular biology of normal melanocytes and melanoma cells. J Clin Pathol. 2013; 66(8):644-8. DOI: 10.1136/jclinpath-2013-201471. View

Rongioletti F, Cecchi F, Rebora A . Halo phenomenon in melanocytic nevi (Sutton's nevi). Does the diameter matter?. J Eur Acad Dermatol Venereol. 2010; 25(10):1231-2. DOI: 10.1111/j.1468-3083.2010.03790.x. View

Barrow C, Browning J, MacGregor D, Davis I, Sturrock S, Jungbluth A . Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006; 12(3 Pt 1):764-71. DOI: 10.1158/1078-0432.CCR-05-1544. View

Requena C, Botella-Estrada R, Traves V, Nagore E, Almenar S, Guillen C . [Problems in defining melanoma regression and prognostic implication]. Actas Dermosifiliogr. 2009; 100(9):759-66. View

Overwijk W, Restifo N . Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol. 2001; 20(6):433-50. PMC: 2543120. View

Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira W, Hearing V . MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem. 2005; 280(14):14006-16. DOI: 10.1074/jbc.M413692200. View

10.

Moretti S, Spallanzani A, Pinzi C, Prignano F, Fabbri P . Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment?. J Cutan Pathol. 2007; 34(4):301-8. DOI: 10.1111/j.1600-0560.2006.00616.x. View

11.

Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D . Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354(7):709-18. DOI: 10.1056/NEJMoa053007. View

12.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

13.

Yang Y, Lin X, Fu W, Luo X, Kang K . An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clin Exp Dermatol. 2009; 35(7):706-10. DOI: 10.1111/j.1365-2230.2009.03671.x. View

14.

Hoashi T, Tamaki K, Hearing V . The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J. 2009; 24(3):916-30. PMC: 2830135. DOI: 10.1096/fj.09-140921. View

15.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

16.

Quaglino P, Ortoncelli M, Comessatti A, Ponti R, Novelli M, Bergallo M . Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology. 2009; 219(3):250-8. DOI: 10.1159/000238305. View

17.

Fontaine D, Parkhill W, Greer W, Walsh N . Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis?. Am J Dermatopathol. 2003; 25(5):371-6. DOI: 10.1097/00000372-200310000-00002. View

18.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

19.

Aouthmany M, Weinstein M, Zirwas M, Brodell R . The natural history of halo nevi: a retrospective case series. J Am Acad Dermatol. 2012; 67(4):582-6. DOI: 10.1016/j.jaad.2011.11.937. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View